ストックスクリーナーアプリを入手
7.16
8.81%
0.58
アフターアワーズ：
7.11
-0.05
-0.70%
前日終値:
$6.58
開ける：
$6.61
24時間の取引高:
532.54K
Relative Volume:
1.22
時価総額：
$84.33M
収益：
$200.00K
当期純損益:
$-26.17M
株価収益率:
-2.7564
EPS:
-2.5976
ネットキャッシュフロー:
$-18.63M
1週間 パフォーマンス:
+23.45%
1か月 パフォーマンス:
+24.31%
6か月 パフォーマンス:
-22.59%
1年 パフォーマンス:
+151.23%
1日の値動き範囲:
$6.6001
$7.50
1週間の範囲:
$5.69
$8.67
52週間の値動き範囲:
$2.2801
$13.50
Clene Inc Stock (CLNN) Company Profile
名前
Clene Inc
セクター
電話
801-676-9695
住所
6550 SOUTH MILLROCK DRIVE, SUITE G50, SALT LAKE CITY
Compare CLNN vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
CLNN
Clene Inc
|
7.16 | 77.50M | 200.00K | -26.17M | -18.63M | -2.5976 |
VRTX
Vertex Pharmaceuticals Inc
|
427.65 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
721.05 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
807.55 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
303.00 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
313.32 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Clene Inc Stock (CLNN) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-10-04 | ダウングレード | Oppenheimer | Outperform → Perform |
| 2022-07-18 | 開始されました | H.C. Wainwright | Buy |
| 2022-05-02 | 開始されました | Canaccord Genuity | Buy |
| 2021-09-28 | 開始されました | Oppenheimer | Outperform |
Clene Inc (CLNN) 最新ニュース
MSN Money - MSN
Clene Conference: CEO Says FDA Minutes Suggest CNM-Au8 Data Could Support ALS NDA Filing - Yahoo Finance
Analysts Are Bullish on Top Consumer Goods Stocks: BRC (BRCC), Clene (CLNN) - The Globe and Mail
CLNN stock rises 8% – here’s what the FDA update means for Clene’s ALS treatment - MSN
Clene Inc. Announces Underwriting Agreement for 1,000,000 Shares of Common Stock on Nasdaq - Minichart
Clene Announces $7 Million Registered Direct Equity Offering - TipRanks
Ugwumba Chidozie sells $530,439 in Clene Inc. shares By Investing.com - Investing.com India
Ugwumba Chidozie sells $530,439 in Clene Inc. shares - Investing.com
SymBiosis II LLC, major Clene (NASDAQ: CLNN) holder, sells 78,679 shares - Stock Titan
Clene Incannounces common stock offeringSEC filing - marketscreener.com
Clene Inc. (NASDAQ: CLNN) files preliminary prospectus for common stock offering - Stock Titan
Clene (NASDAQ: CLNN) prices $7M stock sale to fund CNM-Au8 work - Stock Titan
Clene plans CNM-Au8 filing for accelerated approval in ALS - ALS News Today
Clene Stock Jumps After FDA Opens Door To Accelerated Approval For ALS Drug - Sahm
Clene Announces $7 Million Underwritten Offering of Common Stock - Investing News Network
Clene stock tumbles after pricing $7M stock offering By Investing.com - Investing.com Australia
Clene stock tumbles after pricing $7M stock offering - Investing.com UK
Clene announces $7 million underwritten offering of common stock - marketscreener.com
Clene to Present at Upcoming May Conferences - Investing News Network
Clene prices $7M stock offering to fund drug development - Investing.com
Clene prices $7M stock offering to fund drug development By Investing.com - Investing.com Australia
Clene Inc. Announces Pricing of $7 Million Registered Direct Offering of Common Stock - Quiver Quantitative
Clene sells 1M shares to fund ALS drug filing and Phase 3 trial - Stock Titan
Clene lines up May 6 webcast and New York investor meetings May 7 - Stock Titan
Symbiosis II LLC lists CLNN sales (NASDAQ: CLNN) including 67,991-share lot - Stock Titan
CLNN Maintained by D. Boral Capital -- Price Target Stays at $23 - GuruFocus
Clene Price Target Maintained With a $23.00/Share by D. Boral Capital - Moomoo
Clene Is Maintained at Buy by D. Boral Capital - Moomoo
CLNN Stock Holds Range As Insider Ownership Shifts - StocksToTrade
Clene provides update on NDA for ALS following Type C meeting with FDA - TipRanks
Clene Advances Towards NDA Submission for ALS Treatment (CLNN) - GuruFocus
Clene plans ALS drug application after FDA meeting By Investing.com - Investing.com South Africa
CLNN Stock Rises 8% – Here’s What The FDA Update Means For Clene’s ALS Treatment - Stocktwits
Clene Stock Jumps After FDA Opens Door to Fast-Track ALS Drug Filing - TechStock²
Clene plans ALS drug application after FDA meeting - Investing.com UK
Clene Inc. to Submit Accelerated Approval NDA for ALS Drug CNM-Au8 Following Positive FDA Meeting - Minichart
CLNN Stock Holds Range As Insider Activity Draws Focus - timothysykes.com
After Successful FDA Meeting, Clene Filing Accelerated Approval NDA for ALS - Investing News Network
Clene Advances CNM-Au8 Toward Accelerated ALS Approval - TipRanks
Clene stock surges 20% after FDA meeting on ALS drug approval By Investing.com - Investing.com South Africa
Clene plans ALS drug filing after FDA says data may support faster review - Stock Titan
Clene stock surges 20% after FDA meeting on ALS drug approval - Investing.com
After successful FDA meeting, Clene filing accelerated approval NDA for ALS - marketscreener.com
Clene (NASDAQ: CLNN) to file accelerated ALS drug NDA in 2026 - Stock Titan
Clene Inc. (NASDAQ:CLNN) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Clene Inc (CLNN) 財務データ
収益
当期純利益
現金流量
EPS
1.77%
0.25%
大文字化:
|
ボリューム (24 時間):